Immunogenicity and safety of two versus three doses of 9-valent vaccine against Human papillomavirus (HPV) in women with HIV: the Papillon randomized trial

Deborah Konopnicki; Christine Gilles; Yannick Manigart; Patricia Barlow; Anca Reschner; Coca Necsoi; Marc Delforge; Davy Vanden Broeck; Nicolas Dauby; Stéphane De Wit

doi:10.1093/cid/ciaf241

Immunogenicity and safety of two versus three doses of 9-valent vaccine against Human papillomavirus (HPV) in women with HIV: the Papillon randomized trial

Clin Infect Dis. 2025 May 13:ciaf241. doi: 10.1093/cid/ciaf241. Online ahead of print.

Affiliations

¹ Infectious Diseases department and HIV reference Center, Saint-Pierre University hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium.
² Gynecology department, Saint-Pierre University hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium.
³ Laboratory of molecular pathology AML- Sonic Healthcare Belgium and Belgian national reference laboratory for HPV, Antwerp, Belgium.

PMID: 40356381
DOI: 10.1093/cid/ciaf241

Abstract

Background: WHO recommends 2 doses of HPV vaccine for adults without HIV but 3 doses in persons with HIV. There are no immunogenicity data on the 2 doses schedule in women with HIV (WWH).

Methods: Prospective study comparing 2 (month (M) 0,6) versus 3 (M 0,2,6) doses of 9-valent (9v) vaccine (Gardasil9®MSD) in WWH (15-40 years), on antiretrovirals with HIVRNA<400cp/ml; enrollment 2018-2021. After an open-label phase assessing safety (n=45 receiving 3 doses), participants were randomized between 2 or 3 doses. Primary outcome was non-inferiority of 2 doses compared to 3 doses for seroconversion against all vaccine genotypes. Due to COVID-19 pandemic, 100 WWH, instead of initially planned 120, were randomized. The trial was further amended to give 2 doses to all participants enrolled thereafter (n=22). Results were analyzed in modified intention-to-treat (mITT) on the randomized cohort (n=100) and Per Protocol (PP) on the whole cohort (n=167).

Results: Median age was 35 years, median CD4 count 649/µL, 16 missed M7 visit. In mITT, seroconversion was 97.7% for 2 doses and 97.9% for 3 doses, meeting the predefined non-inferiority criteria. At M7, antibodies titers against all vaccine genotypes were high in both groups (increase by 1.2-2.4 log10). There was no serious adverse event; participants with 3 doses experienced local reaction more frequently (82% versus 60% for 2 doses, p=0.027) with significantly more symptoms and longer duration.

Conclusions: In women with well-controlled HIV, 2 doses of HPV 9v-vaccine is non-inferior to 3 doses in terms of seroconversion and is associated with less reactogenicity.

Keywords: 9-valent vaccine; HIV; HPV; Women; immunogenicity.

© The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.